Dr. Fitzgerald has extensive experience in pharmaceutical research and development and is a co-founder of Synosia. He initially gained a science degree and qualified in medicine, subsequently specializing in gastroenterology. He joined the pharmaceutical industry in the early 1960s and enjoyed an 18-year career in research and development in ICI’s Pharmaceuticals Division (now AstraZeneca), becoming general manager of research and then joining the Pharmaceutical Divisional Board as International Medical Director. He was involved in the discovery of several cardiovascular drugs, including the widely prescribed beta blocker Tenormin®. He has returned to academia at various points in his career, becoming professor of medicine at McMaster University in Canada, and subsequently visiting professor of pharmaco-epidemiology at McGill University in Canada and a visiting professor of pharmacology at the University of Strathclyde in Glasgow. Dr. Fitzgerald is a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine.